Metastatic Pancreatic Adenocarcinoma Clinical Trials

12 recruiting

Metastatic Pancreatic Adenocarcinoma Trials at a Glance

12 actively recruiting trials for metastatic pancreatic adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Rochester, Seattle, and Fairfax. Lead sponsors running metastatic pancreatic adenocarcinoma studies include Mayo Clinic, Barbara Ann Karmanos Cancer Institute, and Astellas Pharma Global Development, Inc..

Browse metastatic pancreatic adenocarcinoma trials by phase

Treatments under study

About Metastatic Pancreatic Adenocarcinoma Clinical Trials

Looking for clinical trials for Metastatic Pancreatic Adenocarcinoma? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Pancreatic Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Pancreatic Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 2

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic Adenocarcinoma
Medical University of South Carolina52 enrolled1 locationNCT07076212
Recruiting
Phase 3

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Pancreatic CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.614 enrolled13 locationsNCT07409272
Recruiting
Phase 3

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Adenocarcinoma+2 more
SWOG Cancer Research Network94 enrolled274 locationsNCT06998940
Recruiting
Phase 1

TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmStage III Pancreatic Cancer AJCC v8+5 more
University of California, Davis52 enrolled1 locationNCT07189195
Recruiting
Phase 2

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8Metastatic Pancreatic Adenocarcinoma
Anne Noonan67 enrolled1 locationNCT04115163
Recruiting
Phase 2

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+3 more
Mayo Clinic25 enrolled1 locationNCT06381154
Recruiting
Phase 2

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Stage IV Pancreatic Cancer AJCC v8Metastatic Pancreatic AdenocarcinomaRecurrent Pancreatic Adenocarcinoma
Mayo Clinic43 enrolled3 locationsNCT07226856
Recruiting
Phase 1Phase 2

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

Stage IV Pancreatic Cancer AJCC v8Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Adenocarcinoma+1 more
M.D. Anderson Cancer Center28 enrolled1 locationNCT03608631
Recruiting
Not Applicable

Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers

Metastatic Pancreatic Adenocarcinoma
City of Hope Medical Center136 enrolled22 locationsNCT06524973
Recruiting
Phase 2

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma
Barbara Ann Karmanos Cancer Institute30 enrolled7 locationsNCT06576115
Recruiting
Phase 3

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma
Eleison Pharmaceuticals LLC.480 enrolled3 locationsNCT01954992
Recruiting
Phase 1

Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma

Metastatic Pancreatic Adenocarcinoma
Chang Gung Memorial Hospital70 enrolled2 locationsNCT06229496